Advertisement

How cancer cells attach to urinary bladder epithelium in vivo: study of the early stages of tumorigenesis in an orthotopic mouse bladder tumor model

  • Andreja Erman
  • Gregor Kapun
  • Sara Novak
  • Mojca Pavlin
  • Goran Dražić
  • Damjana Drobne
  • Peter Veranič
Original Paper
  • 66 Downloads

Abstract

The majority of bladder cancers in humans are non-muscle-invasive cancers that recur frequently after standard treatment procedures. Mouse models are widely used to develop anti-tumor treatments. The purpose of our work was to establish an orthotopic mouse bladder tumor model and to explore early stages of implantation of cancerous MB49 cells in vivo using various labeling and microscopic techniques. To distinguish cancer cells from normal urothelial cells in mouse urinary bladders, we performed molecular characterization of MB49 cells before intravesical injection experiments. In this new approach we applied internalized metal nanoparticles to unequivocally discriminate cancer cells from normal cells. This method revealed that cancer cells attached to the urothelium or basal lamina within just 1 hour of intravesical injection, whereas small tumors and localized hyperplastic urothelial regions developed within two days. We found that cancer cells initially adhere to normal urothelial cells through filopodia and by focal contacts with basal lamina. This is the first in vivo characterization of intercellular contacts between cancerous and normal urothelial cells in the bladder. Our study yields new data about poorly known early events of tumorigenesis in vivo, which could be helpful for the translation into clinic.

Keywords

Orthotopic bladder tumor Mouse model Urinary bladder Urothelium Cancer cells Cell adhesion 

Notes

Acknowledgements

This research work was supported by the Slovenian Research Agency (ARRS) (grant no. P3-0108 and grant no. J3-7494). Authors kindly thank Tjaša Bigec for the help with the fluorescence microscopy analysis. Authors also express gratitude Dr. Julian Venables (Science Sense) for correcting the English.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All applicable international, national, and institutional guidelines for the care and use of animals were followed. Additionally, all procedures performed in studies involving animals were in accordance with the ethical standards of the institution at which the studies were conducted.

References

  1. Amling CL (2001) Diagnosis and management of superficial bladder cancer. Curr Probl Cancer 25(4):219–278CrossRefGoogle Scholar
  2. Bisson JF, Parache RM, Droulle P, Notter D, Vigneron C, Guillemin F (2002) A new method of implanting orthotopic rat bladder tumor for experimental therapies. Int J Cancer 102(3):280–285CrossRefGoogle Scholar
  3. Bregar VB, Lojk J, Šuštar V, Veranič P, Pavlin M (2013) Visualization of internalization of functionalized cobalt ferrite nanoparticles and their intracellular fate. Int J Nanomed 8:919–931Google Scholar
  4. Bryan RT, Atherfold PA, Yeo Y, Jones LJ, Harrison RF, Wallace DM, Jankowski JA (2008) Cadherin switching dictates the biology of transitional cell carcinoma of the bladder: ex vivo and in vitro studies. J Pathol 215(2):184–194CrossRefGoogle Scholar
  5. Chade DC, Andrade PM, Borra RC, Leite KR, Andrade E, Villanova FE, Srougi M (2008) Histopathological characterization of a syngeneic orthotopic murine bladder cancer model. Int Braz J Urol 34(2):220–226 (discussion 226–229) CrossRefGoogle Scholar
  6. Chan E, Patel A, Heston W, Larchian W (2009a) Mouse orthotopic models for bladder cancerGoogle Scholar
  7. Chan ES, Patel AR, Smith AK, Klein JB, Thomas AA, Heston WD, Larchian WA (2009b) Optimizing orthotopic bladder tumor implantation in a syngeneic mouse model. J Urol 182(6):2926–2931CrossRefGoogle Scholar
  8. Cheon J, Moon DG, Cho HY, Park HS, Kim JJ, Gardner TA, Kao C (2002) Adenovirus-mediated suicide-gene therapy in an orthotopic murine bladder tumor model. Int J Urol 9(5):261–267CrossRefGoogle Scholar
  9. Chin J, Kadhim S, Garcia B, Kim YS, Karlik S (1991) Magnetic resonance imaging for detecting and treatment monitoring of orthotopic murine bladder tumor implants. J Urol 145(6):1297–1301CrossRefGoogle Scholar
  10. Dalbagni G, Herr HW (2000) Current use and questions concerning intravesical bladder cancer group for superficial bladder cancer. Urol Clin North Am 27(1):137–146CrossRefGoogle Scholar
  11. Ding J, Xu D, Pan C, Ye M, Kang J, Bai Q, Qi J (2014) Current animal models of bladder cancer: awareness of translatability (Review). Exp Ther Med 8(3):691–699CrossRefGoogle Scholar
  12. Fabris VT, Lodillinsky C, Pampena MB, Belgorosky D, Lanari C, Eiján AM (2012) Cytogenetic characterization of the murine bladder cancer model MB49 and the derived invasive line MB49-I. Cancer Genet 205(4):168–176CrossRefGoogle Scholar
  13. Galbraith CG, Yamada KM, Galbraith JA (2007) Polymerizing actin fibers position integrins primed to probe for adhesion sites. Science 315(5814):992–995CrossRefGoogle Scholar
  14. Gavell GL, Lewis RW, Mechan WL, Leblanc GA (1978) Intravesical thio-tepa in the immediate postoperative period in patients with recurrent transitional cell carcinoma of the bladder. J Urol 120:410–411CrossRefGoogle Scholar
  15. Gϋnther JH, Jurczok A, Wulf T, Brandau S, Deinert I, Jocham D, Böhle A (1999) Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 59(12):2834–2837Google Scholar
  16. Koo V, El Mekabaty A, Hamilton P, Maxwell P, Sharaf O, Diamond J, Watson J, Williamson K (2010) Novel in vitro assays for the characterization of EMT in tumourigenesis. Cell Oncol 32(1–2):67–76PubMedPubMedCentralGoogle Scholar
  17. Lodilinsky C, Rodriguez V, Vauthay L, Sandes E, Casabé A, Eiján AM (2009) Novel invasive orthotopic bladder cancer model with high cathepsin B activity resembling human bladder cancer. J Urol 182(2):749–755CrossRefGoogle Scholar
  18. Lojk J, Bregar VB, Strojan K, Hudoklin S, Veranič P, Pavlin M, Erdani Kreft M (2018) Increased endocytosis of magnetic nanoparticles into cancerous cells versus normal urothelial cells. Histochem Cell Biol 149:45–59CrossRefGoogle Scholar
  19. Loskog A, Ninalga C, Hedlund T, Alimohammadi M, Malmström PU, Tötterman TH (2005) Optimization of the MB49 mouse bladder cancer model for adenoviral gene therapy. Lab Anim 39(4):384–393CrossRefGoogle Scholar
  20. Mangsbo SM, Ninalga C, Essand M, Loskog A, Tötterman TH (2008) CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4 + T-cell immunity. J Immunother 31(1):34–42CrossRefGoogle Scholar
  21. Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH (2010) Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother 33(3):225–235CrossRefGoogle Scholar
  22. Mickey DD, Mickey GH, Murphy WM, Niell HB, Soloway MS (1982) In vitro characterization of four N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) induced mouse bladder tumors. J Urol 127(6):1233–1237CrossRefGoogle Scholar
  23. Mo L, Zheng X, Huang HY, Shapiro E, Lepor H, Cordon-Cardo C, Sun TT, Wu XR (2007) Hyperactivation of Ha-ras oncogene, but not Ink4a/Arf deficiency, triggers bladder tumorigenesis. J Clin Invest 117(2):314–325CrossRefGoogle Scholar
  24. Nativ O, Dalal E, Hidas G, Aronson M (2006) EDTA-induced urothelial cell shedding for the treatment of superficial bladder cancer in the mouse. Int J Urol 13(10):1344–1346CrossRefGoogle Scholar
  25. Soloway MS (1977) Intravesical and systemic chemotherapy of murine bladder cancer. Cancer Res 37(8 Pt 2):2918–2929PubMedGoogle Scholar
  26. Soloway MS, Masters S (1980) Urothelial susceptibility to tumor cell implantation: influence of cauterization. Cancer 46(5):1158–1163CrossRefGoogle Scholar
  27. Soloway MS, Nissenkorn I, McCallum L (1983) Urothelial susceptibility to tumor cell implantation: comparison of cauterization with N-methyl-N-nitrosourea. Urology 21(2):159–161CrossRefGoogle Scholar
  28. Summerhays IC, Franks LM (1979) Effects of donor age on neoplastic transformation of adult mouse bladder epithelium in vitro. J Natl Cancer Inst 62(4):1017–1023Google Scholar
  29. Thiery JP (2002) Epithelial–mesenchymal transitions in tumour progression. Nat Rev Cancer 2(6):442–454CrossRefGoogle Scholar
  30. Vasioukhin V, Bauer C, Yin M, Fuchs E (2000) Directed actin polymerization is the driving force for epithelial cell–cell adhesion. Cell 100(2):209–219CrossRefGoogle Scholar
  31. Watanabe T, Shinohara N, Sazawa A, Harabayashi T, Ogiso Y, Koyanagi T, Takiguchi M, Hashimoto A, Kuzumaki N, Yamashita M, Tanaka M, Grossman HB, Benedict WF (2000) An improved intravesical model using human bladder cancer cell lines to optimize gene and other therapies. Cancer Gene Ther 7(12):1575–1580CrossRefGoogle Scholar
  32. Werthman PE, Drazan KE, Rosenthal JT, Khalili R, Shaked A (1996) Adenoviral-p53 gene transfer to orthotopic and peritoneal murine bladder cancer. J Urol 155(2):753–756CrossRefGoogle Scholar
  33. Xiao Z, McCallum TJ, Brown KM, Miller GG, Halls SB, Parney I, Moore RB (1999) Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer 81(4):638–646CrossRefGoogle Scholar
  34. Yu DS, Lee CF, Chang SY (2007) Immunotherapy for orthotopic murine bladder cancer using bacillus Calmette-Guerin recombinant protein Mpt-64. J Urol 177(2):738–742CrossRefGoogle Scholar
  35. Zhang N, Li D, Shao J, Wang X (2015) Animal models for bladder cancer: The model establishment and evaluation (Review). Oncol Lett 9(4):1515–1519CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Institute of Cell Biology, Faculty of MedicineUniversity of LjubljanaLjubljanaSlovenia
  2. 2.National Institute of ChemistryLjubljanaSlovenia
  3. 3.Department of Biology, Biotechnical facultyUniversity of LjubljanaLjubljanaSlovenia
  4. 4.Faculty of Electrical EngineeringUniversity of LjubljanaLjubljanaSlovenia

Personalised recommendations